Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) has been recognized again as a “Caring Company” by The Hong Kong Council of Social Service (HKCSS). Lee’s Pharm attained Caring Company Award Logo for consecutive two years with good corporate citizenship recognition.

LOS ALTOS, Calif., July 18, 2022 -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that the Company has entered into an agreement granting exclusive rights to develop, market and commercialize Renazorb® (lanthanum dioxycarbonate) to Lee's Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm”)(SEHK: 950), in Mainland China, Hong Kong, and certain other Asian markets. Renazorb is Unicycive’s novel phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients.

Hong Kong, July 12, 2022, Menet, the healthcare information platform announced the annual ranking series of Chinese Pharmaceutical Industry in 2021. Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) continued to hold the award of “Top 100 Chinese Chemical Pharmaceutical Companies” in the year 2021. The Group has been the winner of this award for three consecutive years since 2019.

The 2022 China Medical and Health Industry Symbiosis Conference, organized by Menet, the healthcare information platform was held in Huzhou, Zhejiang Province, China from 12 to 15 July, 2022. The lists of “Top 100 ranking of Chinese Pharmaceutical Industry”, “Top Brand of Chinese Pharmaceuticals” and “2022 Most Valuable Product in Partnership for Drug Store Chain in China” were released. The in-licensed product of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), Ferplex® was elected as “2022 Most Valuable Product in Partnership for Drug Store Chain in China”.

TOKYO & HONG KONG, June 30, 2022 ‐ Lee’s Pharmaceutical Holdings Limited (SEHK stock code: 0950, Headquarters: Hongkong, Executive Managing Director: Lee lalertsuphakun Wanee, hereinafter “Lee’s Pharm”) and Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) jointly announced today that Solasia and Lee’s Pharm have entered into a business transfer agreement for the rights of promoting, distributing and selling of Sancuso® and episil® in Beijing, Shanghai and Guangzhou in the People’s Republic of China.

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) is pleased to announce that, on 31 May 2022, the Drug Registration Certificate for in-licensed product Teglutik® (Riluzole Oral Suspension) has been obtained from the China National Medical Products Administration (NMPA). Teglutik® has been approved to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (“ALS”).

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) is pleased to announce that, the Drug Registration Certificate for in-licensed product Natulan® (Procarbazine Capsules) has been obtained from the China National Medical Products Administration (“NMPA”). Natulan® has been approved for use in combination with other anticancer drugs to treat Hodgkin’s Lymphoma (“HL”).

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) announced that, the registration of in-licensed product “Nitric Oxide for Inhalation” (INOmax®) was approved for commercialization by China National Medical Products Administration (NMPA). INOmax®, the first medicinal gas product approved in China, is an inhaled nitric oxide pharmaceutical for treating term and near-term neonates (>34weeks) with hypoxic respiratory failure ("HRF") associated with pulmonary hypertension (PPHN). It is indicated to improve oxygenation and reduce the need for extra-corporeal membrane oxygenation (ECMO) of patients.

Hong Kong, March 22, 2022, the Retail Sales Department of the Group Commercial Operations Centre, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”) signed the Comprehensive Strategic Cooperation Agreement with Guangdong Rongtai Pharmaceutical Company Limited (“Rongtai Pharmaceutical”).

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”) aims at expanding the distribution channels and offering wide array of health and pharmaceutical products to meet the variety of needs. The Group launched the flagship store on Ali’s and Jingdong’s e-commerce platforms in China on March 23, 2022. Dr. Li Xiaoyi, the founder and Ms. Leelalertsuphakun Wanee, the Managing Director of the Group joined the Virtual Grand Opening Ceremony of Lee’s Pharm Flagship Store held in Guangzhou Sales Office. By establishing Lee’s Pharm flagship store, the Group has reached a new milestone with the development of new retail and is looking forward to connecting the public and the patients in needed.

Recently, the Anhui Provincial Department of Economy and Information Technology announced the list of “Anhui Provincial Role Model Enterprise in Consumer Products Industry” through online platform. Zhaoke Pharmaceutical (Hefei) Company Limited (“Zhaoke-Hefei”), the subsidiary of Lee’s Pharmaceutical Holdings Limited was one of the few pharmaceutical companies to receive this honour.

Hong Kong, December 23, 2021, the “2020-2021 Top Brand List of Family Choice Pharmacy in China”, jointly organized by familydoctor.com.cn and Sinomonitor, was officially announced through online platform. Two of the signature products from Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”) are granted admission into the guidance list. The in-licensed product Ferplex® and the in-house proprietary product Yallaferon®, are listed in the “Health Supplement Category” and “Gynecological Category” respectively.